20-22 May, San Diego 

Jenny King presented work discussing the burden and mechanisms of cough in Idiopathic Pulmonary Fibrosis (IPF) and about tests that could be used with further development to identify those who may benefit from new cough treatments. Jacky Smith presented data about a new treatment Nalbuphine trialled to treat cough in IPF and how this significantly reduced cough bouts (groups of coughs).

Other new research discussed was PACIFY cough which trialled Morphine Sulphate Modified Release to Treat cough in IPF which showed a significant reduction in cough in this group. Data was also presented on a new cough treatment in clinical trials (camlipixant) a P2X3 anatagonist which has been shown to treat cough and reduce urinary incontinence in chronic cough patients in phase 2 studies. A Phase 3 study is ongoing.

Chronic cough has a huge impact on quality of life. Appropriate validated tools to quantify this in clinical trials of new treatments are currently lacking. McMaster University presented their work on the development of a tool that adequately assess’ and captures quality of life in patients with chronic cough in an FDA approved format that can be used in trials to help with licensing applications of new cough treatments.

https://site.thoracic.org/events/ats-2024-international-conference